ClinicalTrials.gg
CompletedNCT01686932CGM-VISITUpdated Mar 2, 2016Results posted

Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function

A Phase 4 interventional study of Vildagliptin and Sitagliptin in Diabetes Mellitus Type 2, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in Germany. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-03-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Vildagliptin · Diabetes Mellitus, Type 2.

Enrollment
84th of 118
51 · median 162
Started
2012
with 9 others
Phase 4
43 of 119
none open now
Registered
90th of 119
by date
Lead sponsor
47 of 119
Novartis Pharmaceuticals

Among the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2, this one is the 84th largest by enrollment of the 118 interventional ones that give a count, is one of 10 that started in 2012, is one of 43 in phase 4, and was the 90th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About vildagliptin

Vildagliptin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

Vildagliptin and Sitagliptin both belong to the class of DPP-4 inhibitors, but differ in their pharmacokinetic profile as well as in their approved application (Vildagliptin, 2x 50 mg daily, Sitagliptin, 1x 100 mg daily). This leads to distinct results regarding postprandial blood-glucose normalization as well as protective properties regarding hypoglycemic episodes - especially during the night. Additionally, in type 1 diabetic patients a correlation has been described between hypoglycemia and abnormal heart function (QTc-elongation), which can have severe consequences for the patients. This study aims for the evaluation of the potency of both drugs to prevent and/or reduce hypoglycemic events in insulin-dependent type-2 diabetics and furthermore to evaluate the correlation of hypoglycemic episodes with changes in heart-function measured by Holter-ECG.

The hypothesis is tested, if vildagliptin leads to a more favourable glycemic profile than sitagliptin and is more potent in protecting from nocturnal abnormalities in heart-function caused by undetected hypoglycemic episodes.

03

Conditions studied

  • Diabetes Mellitus Type 2

Keywords

  • vildagliptin
  • sitagliptin
  • continuous glucose monitoring (CGM)
  • glycemic fluctuations
  • MAGE
  • impact of hypoglycemia on heart function (cardiac dysfuction measured via ECG)
  • difference in glycemic profile of vildagliptin compared to sitagliptin
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Written must be obtained before any assessment is performed.

      1. Ability to comply with all study requirements. 3. Patients with Type 2 diabetes treated with stable, once or twice daily doses (minimal dose of 0.3 unit/kg/day) of basal long-acting or intermediate-acting insulin alone or in pre-mixed combination with rapid-acting or short-acting insulin for at least 12 weeks prior to Visit 1. Stable is defined as ±10% of the Visit 1 dose during the previous 12 weeks.
      1. Patients receiving metformin must be on a stable dose of metformin (at least 1500 mg daily or a maximally tolerated dose) for at least 12 weeks prior to Visit 1. 5. ≥7.5 to ≤ 9,0% at Visit 1 6. Known CV disease based on a documented history of one or more of pre-defined criteria 7. Age: ≥40 to ≤80 years at Visit 1

Exclusion criteria

Exclusion Criteria:

    1. FPG ≥ 270 mg/dL (15 mmol/L) at Visit 1. 2. Use of any of the following medications as assessed at Visit 1:

      1. rapid or short acting insulin except in pre-mixed formulations with intermediate or long-acting insulin; insulin administration more frequently than twice-daily, or total insulin dose \< 0.3 unit/kg/day for the past 12 weeks
      2. use of any oral antidiabetic medication or GLP-1 analogues within the last 12 weeks, except metformin
      3. use of weight control products including weight-loss medications in the last 12 weeks.
      4. use of oral (≥7 consecutive days) or chronic parenteral or intra-articular treatment within the last 8 weeks. Inhaled or topical steroids without systemic effects will be allowed.
      5. treatment with growth hormone within the previous 6 months.
      6. treatment with any drug of known and frequent toxicity to a major organ, or that may interfere with the interpretation of the efficacy and safety data during the study.

        1. a history or evidence of any of the following at Visit 1:

      <!-- -->

      1. acute metabolic conditions such a ketoacidosis, lactic acidosis or hyperosmolar state (including precoma and coma) within the past 6 months.
      2. current diagnosis of congestive heart failure ( III or IV).
      3. myocardial infarction within the past 6 months.
      4. coronary artery bypass surgery or percutaneous coronary intervention within the past 6 months.
      5. Stroke, , or reversible ischemic neurologic deficit within the past 6 months.
      6. unstable angina within the past 6 months.
      7. sustained and ventricular arrhythmia (patients with premature ventricular contractions if deemed not clinically significant may be enrolled).
      8. Patients with permanent atrial fibrillation or pacemaker.
      9. active substance abuse, alcohol abuse and history of alcohol-related diseases within the past 2 years.
      10. type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes (e.g. Cushing's syndrome or acromegaly-associated diabetes).
      11. of an organ system (other than localized basal cell carcinoma of the skin) treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
      12. hepatic disorder defined as:

        • acute or chronic liver disease, evidence of hepatitis, cirrhosis or portal hypertension.
        • history of imaging abnormalities that suggest liver disease (except hepatic steatosis), such as portal hypertension, capsule scalloping, cirrhosis.
      13. acute infections which may affect blood glucose control within the past 4 weeks.

        1. any of the following significant laboratory abnormalities as assessed at Visit 1:

      <!-- -->

      1. clinically significant increase or reduction in thyroid stimulating hormone (TSH) outside of the normal range.
      2. clinically significant renal dysfunction: (GFR) \<50 mL/min/1.73m2 (via MDRD formula).
      3. Patients on metformin with a GFR \<60 mL/min/1.73m2 (via MDRD formula).
      4. (ALT) and/or aspartate aminotransferase (AST) > 2 x (ULN) at Visit 1, confirmed by repeated measurements within 3 working days.
      5. total > 2 x ULN and/or direct bilirubin > 1 x ULN confirmed by repeated measurements within 3 working days.
      6. positive surface antigen (HBsAg).
      7. positive virus (HCV) antibody test (anti-HCV).
      8. elevated fasting triglycerides (TGs) > 500mg/dL (5.65mmol/L), confirmed by a repeated measurements within 3 working days.
      9. clinically significant laboratory abnormalities which, in the opinion of the investigator, cause the patient to be considered inappropriate for inclusion in the study.

        1. any of the following electrocardiographic abnormalities at Visit 1:

      <!-- -->

      1. second or third degree atrio-ventricular block.
      2. A of > 440 ms.
      3. clinically significant (ECG) abnormalities which, in the opinion of the investigator, may cause the patient to be considered inappropriate for inclusion in the study

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Vildagliptin followed by Sitagliptin

    Period 1: vildagliptin 50mg BID for 8 weeks; followed by Washout then Period 2: sitagliptin 100mg QD for 8 weeks

    Drug: Vildagliptin · Drug: Sitagliptin

  • Experimental
    Sitagliptin followed by Vildagliptin

    Period 1: sitagliptin 100mg QD for 8 weeks; followed by Washout then Period 2: vildagliptin 50mg BID for 8 weeks

    Drug: Vildagliptin · Drug: Sitagliptin

Interventions

  • vildagliptin 50mg BID for 8 weeks

    Also known as: Vildagliptin (Galvus) LAF237

  • sitagliptin 100mg QD for 8 weeks

    Also known as: sitagliptin, Januvia

06

What researchers measure

Primary outcomes

  1. Hypoglycemic Profile of Vildagliptin Compared to Sitagliptin Over 4 Days After 8 Weeks of Treatment in Period 1 & 2

    The hypoglycemic profile is defined as the area under the curve glucose-time profile obtained by continuous glucose monitoring Interstitial glucose values below 3.9 mmol/L (averaged over 5 minutes) were considered relevant for the estimation of the interstitial glucose AUC in the hypoglycemic range These AUC\<3.9mmol/L/5min. values were summed up over 4 days (unit: mmol/L/4d) or over 24 hours at measurement Days 2, 3, 4, and 5 (unit: mmol/L/24h). Lower values for AUC reflect less intense hypoglycemia.

    Time frame: baseline and 0-24 hours post-dose on Days 2 to 5

Secondary outcomes

  1. Number of Hypoglycemic Events During Vildagliptin Treatment Compared to Sitagliptin Treatment.

    Hypoglycemic events are defined as blood glucose values \<70 mg/dL measured by a self-monitored blood glucose (SMBG) or continuous glucose monitoring (CGM) measurement regardless of any symptoms suggestive of low blood glucose.

    Time frame: after 8 weeks period 1 and Period 2

  2. Mean Duration of Hypoglycemic Events (Min.) Measured With Continuous Glucose Monitoring (CGM) Over 4 Days After 8 Weeks of Treatment for Period 1 & Period 2

    the mean duration of hypoglycemic events is detected by continuous glucose monitoring (CGM)measurement.

    Time frame: after 8 weeks for Period 1 & Period 2

  3. Mean Amplitudes of Hypoglycemic Events (mmol/L) Measured With Continuous Glucose Monitoring (CGM) Over 4 Days After 8 Weeks of Treatment for Period 1 & Period 2

    To evaluate by CGM measurement the grade of severity of hypoglycemia measured as the mean amplitude over 4 days after 8 weeks of treatment in Period 1 \& Period 2

    Time frame: after 8 weeks Period 1 & Period 2

  4. Number of Severe Hypoglycemic Events During Vildagliptin Treatment Compared to Sitagliptin Treatment After 8 Weeks of Treatment in Period 1 and Period 2

    Severe hypoglycemic events are defined as any episode requiring the assistance of another party or measured plasma glucose levels of \<40 mg /dL. Assessed by self-monitored blood glucose (SMBG)After 8 weeks of treatment in Period 1 and Period 2

    Time frame: after 8 weeks Period 1 & Period 2

  5. Glucose Fluctuations During the Day Under Vildagliptin Treatment Compared to Sitagliptin Treatment on Day 2 After 8 Weeks of Treatment Period 1 & Period 2

    Glucose fluctuations are assessed by the mean amplitude of glycemic excursions (MAGE) and standard deviations (SD) (Service et al., 1970). on day 2 after 8 weeks of treatment Period 1 \& Period 2

    Time frame: Day 2 after 8 weeks of treatment Period 1 & Period 2

  6. Number of Participants With ECG Abnormalities Depending on Hypoglycemic Events After 8 Weeks of Treatment Period 1 & Period 2

    ECG abnormalities are defined as either: • Occurrence of \>30 ventricular extrasystoles (VES) per hour or • Occurrence of ≥2 consecutive VES (Couplets) or • Occurrence of ≥3 consecutive VES (Triplets) or • QT-time corrected for heart rate (QTc) \>440 ms. after 8 weeks of treatment Period 1 \& Period 2

    Time frame: after 8 weeks of treatment Period 1 & Period 2

  7. Change From Baseline of Inflammatory Biomarkers High Sensitivity C-reactive Protein (hsCRP) After 8 Weeks of Treatment in Period 1 & Period 2

    The inflammatory biomarkers hsCRP was assessed at baseline and after 8 weeks of treatment Period 1 \& Period 2

    Time frame: Baseline, after 8 weeks Period 1 & Period 2

  8. Change From Baseline of Inflammatory Biomarkers Interleukin 6 (IL-6) After 8 Weeks of Treatment in Period 1 & Period 2

    The inflammatory biomarkers IL-6 was assessed at baseline and after 8 weeks of treatment Period 1 \& Period 2

    Time frame: Baseline, after 8 weeks Period 1 & Period 2

  9. Percentage Change From Baseline of Pro-insulin/C-peptide Ratios After 8 Weeks of Treatment Period 1 & Period 2

    Percentage Change from baseline of pro-insulin/C-peptide ratios after 8 weeks of treatment Period 1 \& Period 2 Higher pro-insulin / C-peptide ratios (expressing disproportional hyperproinsulinemia) may be associated with increasing beta cell dysfunction and more inefficient pro-insulin processing

    Time frame: Baseline, after 8 weeks Period 1 & Period 2

  10. Number of Occurrence of Pre-defined ECG Findings During 4 Days of Continuous ECG Monitoring at Baseline and in the 8th Week of Periods 1 and 2

    Number of Occurrence of pre-defined ECG findings during 4 days of continuous ECG monitoring at baseline and in the 8th week of Periods 1 and 2. ECG data were continuously recorded and analyzed over a period of 4 days simultaneously with continuous glucose monitoring. It assessed number of any Vertical Electric(al) Sounding (VES), number of 2 consecutive VES \[couplets\], and number of \>3 consecutive VES \[salves\]

    Time frame: after 8 weeks Period 1 & Period 2

07

Results

Posted Oct 2, 2015

Participant flow

Period 1: 8 weeks treatment with vildagliptin 50mg BID or sitagliptin 100mg QD, 1-4 weeks wash-out, followed by Period 2, 8 weeks treatment with sitagliptin 100mg QD or vildagliptin 50mg BID

Period 1
Participant flow — Period 1
MilestoneVildagliptin Followed by SitagliptinSitagliptin Followed by Vildagliptin
Started2526
Completed2425
Not completed11
Withdrew: Adverse event11
Period 2
Participant flow — Period 2
MilestoneVildagliptin Followed by SitagliptinSitagliptin Followed by Vildagliptin
Started2425
Completed2425
Not completed00

Outcome measures

PrimaryHypoglycemic Profile of Vildagliptin Compared to Sitagliptin Over 4 Days After 8 Weeks of Treatment in Period 1 & 2

The hypoglycemic profile is defined as the area under the curve glucose-time profile obtained by continuous glucose monitoring Interstitial glucose values below 3.9 mmol/L (averaged over 5 minutes) were considered relevant for the estimation of the interstitial glucose AUC in the hypoglycemic range These AUC\<3.9mmol/L/5min. values were summed up over 4 days (unit: mmol/L/4d) or over 24 hours at measurement Days 2, 3, 4, and 5 (unit: mmol/L/24h). Lower values for AUC reflect less intense hypoglycemia.

Time frame:
baseline and 0-24 hours post-dose on Days 2 to 5
Reported as:
Mean · mmol/L/4d
Hypoglycemic Profile of Vildagliptin Compared to Sitagliptin Over 4 Days After 8 Weeks of Treatment in Period 1 & 2
mmol/L/4dVitagliptinSitagliptin
Hypoglycemic Profile of Vildagliptin Compared to Sitagliptin Over 4 Days After 8 Weeks of Treatment in Period 1 & 211.2 ± 25.655.3 ± 11.70
SecondaryNumber of Hypoglycemic Events During Vildagliptin Treatment Compared to Sitagliptin Treatment.

Hypoglycemic events are defined as blood glucose values \<70 mg/dL measured by a self-monitored blood glucose (SMBG) or continuous glucose monitoring (CGM) measurement regardless of any symptoms suggestive of low blood glucose.

Time frame:
after 8 weeks period 1 and Period 2
Reported as:
Number · number of hypoglycemic events
Number of Hypoglycemic Events During Vildagliptin Treatment Compared to Sitagliptin Treatment.
number of hypoglycemic eventsVitagliptinSitagliptin
continuous glucose monitoring (CGM)6937
self-monitored blood glucose (SMBG)2913
SecondaryMean Duration of Hypoglycemic Events (Min.) Measured With Continuous Glucose Monitoring (CGM) Over 4 Days After 8 Weeks of Treatment for Period 1 & Period 2

the mean duration of hypoglycemic events is detected by continuous glucose monitoring (CGM)measurement.

Time frame:
after 8 weeks for Period 1 & Period 2
Reported as:
Mean · minutes
Mean Duration of Hypoglycemic Events (Min.) Measured With Continuous Glucose Monitoring (CGM) Over 4 Days After 8 Weeks of Treatment for Period 1 & Period 2
minutesVitagliptinSitagliptin
Mean Duration of Hypoglycemic Events (Min.) Measured With Continuous Glucose Monitoring (CGM) Over 4 Days After 8 Weeks of Treatment for Period 1 & Period 229.1 ± 44.7128.0 ± 51.45
SecondaryMean Amplitudes of Hypoglycemic Events (mmol/L) Measured With Continuous Glucose Monitoring (CGM) Over 4 Days After 8 Weeks of Treatment for Period 1 & Period 2

To evaluate by CGM measurement the grade of severity of hypoglycemia measured as the mean amplitude over 4 days after 8 weeks of treatment in Period 1 \& Period 2

Time frame:
after 8 weeks Period 1 & Period 2
Reported as:
Mean · mmol/L
Mean Amplitudes of Hypoglycemic Events (mmol/L) Measured With Continuous Glucose Monitoring (CGM) Over 4 Days After 8 Weeks of Treatment for Period 1 & Period 2
mmol/LVitagliptinSitagliptin
Mean Amplitudes of Hypoglycemic Events (mmol/L) Measured With Continuous Glucose Monitoring (CGM) Over 4 Days After 8 Weeks of Treatment for Period 1 & Period 20.2 ± 0.320.2 ± 0.36
SecondaryNumber of Severe Hypoglycemic Events During Vildagliptin Treatment Compared to Sitagliptin Treatment After 8 Weeks of Treatment in Period 1 and Period 2

Severe hypoglycemic events are defined as any episode requiring the assistance of another party or measured plasma glucose levels of \<40 mg /dL. Assessed by self-monitored blood glucose (SMBG)After 8 weeks of treatment in Period 1 and Period 2

Time frame:
after 8 weeks Period 1 & Period 2
Reported as:
Number · severe hypoglycemic events
Number of Severe Hypoglycemic Events During Vildagliptin Treatment Compared to Sitagliptin Treatment After 8 Weeks of Treatment in Period 1 and Period 2
severe hypoglycemic eventsVitagliptinSitagliptin
Number of Severe Hypoglycemic Events During Vildagliptin Treatment Compared to Sitagliptin Treatment After 8 Weeks of Treatment in Period 1 and Period 211
SecondaryGlucose Fluctuations During the Day Under Vildagliptin Treatment Compared to Sitagliptin Treatment on Day 2 After 8 Weeks of Treatment Period 1 & Period 2

Glucose fluctuations are assessed by the mean amplitude of glycemic excursions (MAGE) and standard deviations (SD) (Service et al., 1970). on day 2 after 8 weeks of treatment Period 1 \& Period 2

Time frame:
Day 2 after 8 weeks of treatment Period 1 & Period 2
Reported as:
Mean · mmol/L
Glucose Fluctuations During the Day Under Vildagliptin Treatment Compared to Sitagliptin Treatment on Day 2 After 8 Weeks of Treatment Period 1 & Period 2
mmol/LVitagliptinSitagliptin
Glucose Fluctuations During the Day Under Vildagliptin Treatment Compared to Sitagliptin Treatment on Day 2 After 8 Weeks of Treatment Period 1 & Period 24.7 ± 1.694.6 ± 1.36
SecondaryNumber of Participants With ECG Abnormalities Depending on Hypoglycemic Events After 8 Weeks of Treatment Period 1 & Period 2

ECG abnormalities are defined as either: • Occurrence of \>30 ventricular extrasystoles (VES) per hour or • Occurrence of ≥2 consecutive VES (Couplets) or • Occurrence of ≥3 consecutive VES (Triplets) or • QT-time corrected for heart rate (QTc) \>440 ms. after 8 weeks of treatment Period 1 \& Period 2

Time frame:
after 8 weeks of treatment Period 1 & Period 2
Reported as:
Number · participants
Number of Participants With ECG Abnormalities Depending on Hypoglycemic Events After 8 Weeks of Treatment Period 1 & Period 2
participantsVitagliptinSitagliptin
Patients with hypoglycemia (n=21,17)1410
Patients without hypoglycemia (n=28,32)1924
SecondaryChange From Baseline of Inflammatory Biomarkers High Sensitivity C-reactive Protein (hsCRP) After 8 Weeks of Treatment in Period 1 & Period 2

The inflammatory biomarkers hsCRP was assessed at baseline and after 8 weeks of treatment Period 1 \& Period 2

Time frame:
Baseline, after 8 weeks Period 1 & Period 2
Reported as:
Mean · mg/L
Change From Baseline of Inflammatory Biomarkers High Sensitivity C-reactive Protein (hsCRP) After 8 Weeks of Treatment in Period 1 & Period 2
mg/LVitagliptinSitagliptin
Change From Baseline of Inflammatory Biomarkers High Sensitivity C-reactive Protein (hsCRP) After 8 Weeks of Treatment in Period 1 & Period 20.79 ± 4.960.60 ± 2.48
SecondaryChange From Baseline of Inflammatory Biomarkers Interleukin 6 (IL-6) After 8 Weeks of Treatment in Period 1 & Period 2

The inflammatory biomarkers IL-6 was assessed at baseline and after 8 weeks of treatment Period 1 \& Period 2

Time frame:
Baseline, after 8 weeks Period 1 & Period 2
Reported as:
Mean · pg/L
Change From Baseline of Inflammatory Biomarkers Interleukin 6 (IL-6) After 8 Weeks of Treatment in Period 1 & Period 2
pg/LVitagliptinSitagliptin
Change From Baseline of Inflammatory Biomarkers Interleukin 6 (IL-6) After 8 Weeks of Treatment in Period 1 & Period 20.40 ± 3.900.08 ± 0.93
SecondaryPercentage Change From Baseline of Pro-insulin/C-peptide Ratios After 8 Weeks of Treatment Period 1 & Period 2

Percentage Change from baseline of pro-insulin/C-peptide ratios after 8 weeks of treatment Period 1 \& Period 2 Higher pro-insulin / C-peptide ratios (expressing disproportional hyperproinsulinemia) may be associated with increasing beta cell dysfunction and more inefficient pro-insulin processing

Time frame:
Baseline, after 8 weeks Period 1 & Period 2
Reported as:
Mean · Percentage Change
Percentage Change From Baseline of Pro-insulin/C-peptide Ratios After 8 Weeks of Treatment Period 1 & Period 2
Percentage ChangeVitagliptinSitagliptin
Percentage Change From Baseline of Pro-insulin/C-peptide Ratios After 8 Weeks of Treatment Period 1 & Period 2-0.34 ± 0.47-0.31 ± 0.57
SecondaryNumber of Occurrence of Pre-defined ECG Findings During 4 Days of Continuous ECG Monitoring at Baseline and in the 8th Week of Periods 1 and 2

Number of Occurrence of pre-defined ECG findings during 4 days of continuous ECG monitoring at baseline and in the 8th week of Periods 1 and 2. ECG data were continuously recorded and analyzed over a period of 4 days simultaneously with continuous glucose monitoring. It assessed number of any Vertical Electric(al) Sounding (VES), number of 2 consecutive VES \[couplets\], and number of \>3 consecutive VES \[salves\]

Time frame:
after 8 weeks Period 1 & Period 2
Reported as:
Mean · number of occurrence
Number of Occurrence of Pre-defined ECG Findings During 4 Days of Continuous ECG Monitoring at Baseline and in the 8th Week of Periods 1 and 2
number of occurrenceVitagliptinSitagliptin
# any VES Per.1 n=23, 25879.7 ± 1405.22786.7 ± 6507.7
# any VES Per.2 n=25, 234389.9 ± 166921060.2 ± 1812.4
# couplets VES Per.1 n=23, 2512.8 ± 32.5115.0 ± 405.9
# couplets VES Per.2 n=25, 236.7 ± 10.32.4 ± 3.0
# salves VES Per.1 n=23, 251.0 ± 2.415.8 ± 52.6
# salves VES Per.2 n=25, 230.8 ± 1.70.9 ± 1.9

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vildagliptin—2/50 (4%)16/50 (32%)
Sitagliptin—1/50 (2%)9/50 (18%)
Most frequent serious events
Most frequent serious events
EventVildagliptinSitagliptin
CORONARY ARTERY DISEASECardiac disorders1/500/50
MYOCARDIAL INFARCTIONCardiac disorders1/500/50
PERICARDITISCardiac disorders1/500/50
HYPOGLYCAEMIAMetabolism and nutrition disorders0/501/50
LUNG NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/500/50
TRANSIENT ISCHAEMIC ATTACKNervous system disorders0/501/50
Most frequent other events
Most frequent other events
EventVildagliptinSitagliptin
HYPOGLYCAEMIAMetabolism and nutrition disorders13/507/50
BLOOD GLUCOSE DECREASEDInvestigations4/503/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vildagliptin Followed by SitagliptinSitagliptin Followed by VildagliptinTotal
Mean64.8 ± 6.065.2 ± 8.665 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)Vildagliptin Followed by SitagliptinSitagliptin Followed by VildagliptinTotal
Female4610
Male212041
08

Study locations

11 sites
  • Novartis Investigative Site
    Berlin, 10115, Germany
  • Novartis Investigative Site
    Berlin, 13055, Germany
  • Novartis Investigative Site
    Dortmund, 44137, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Elsterwerda, 04910, Germany
  • Novartis Investigative Site
    Falkensee, 14612, Germany
  • Novartis Investigative Site
    Magdeburg, 39112, Germany
  • Novartis Investigative Site
    Neuss, 41460, Germany
  • Novartis Investigative Site
    Potsdam, 14469, Germany
  • Novartis Investigative Site
    Sulzbach-Rosenberg, 92237, Germany
  • Novartis Investigative Site
    Wallerfing, 94574, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2012
First posted
Sep 18, 2012
Start
Nov 2012
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Results first posted
Oct 2, 2015
Last update
Mar 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01686932
Responsible party
Sponsor
First posted
Sep 18, 2012
Start date
Nov 2012
Primary completion
Sep 2014
Completion
Sep 2014
Results posted
Oct 2, 2015
Last update
Mar 2, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vildagliptin · Sitagliptin

Start the discussion